


36. Morrell LM, **Ardalan B**, Richman SP, Fleming TR, MacDonald JS: A Phase II multi-institutional trial of low dose N-(Phosphonacetyl)-L-Aspartate and high dose 5-Fluorouracil as a short-term infusion in the


48. Ardalan B, Flores M: A new complication of permanent indwelling


60. Feun L, O’Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER,


72. A Phase II study of irinotecan, high-dose 24-hours continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. **Bach Ardalan, MD**, Olga Kozyreva, MD, Kao-Tai Tsai, PhD, Edgardo S. Santos, MD, Dido Franceschi, MD, Alan Livingstone, MD, Mayra Lima, MSN- Anti-Cancer Drugs, 2007 Sep;18 (8):955-961

73. Neoadjuvant, Surgery, and Adjuvant Chemotherapy without Radiation for Esophageal Cancer. **B Ardalan, MD**; Seth A. Spector, MD; Alan S. Livingstone, MD; Dido Franceschi, MD; Dmitry Mezentsev, MD; Mayra Lima, ARNP; Carol P. Bowen-Wells, MD; Lynne Sparling, RN; Eli Avisar, MD; Gail Walker, PhD; Parvin Ganjei-Azar, MD; Japanese Journal of Clinical Oncology. 2007 Aug 18


**Other works, publications and abstracts:**


uridine levels as the predictor of response in patients treated with 5-FU and PALA. *AACR* 23:8 (30), 1982.


47. Tian E, Higashi Y, Yoshioka M, Ariyoshi M, Murakami T, Yatas N, **Ardalan B**:


57. Tian E, Ardalan K, Hochman I, Tejada F, Ardalan B: In vitro comparison of low dose 24 hr exposure vs high dose 1 hr exposure of a melanoma cell line to 5-fluorouracil (5FU), stimulating our clinical studies. AACR 33:545 (3260), 1992.


59. Feun LG, Reddy KR, Yrizzary JM, Savaraj N, Guerra JJ, Purser RK, Waldman S,


62. Ucar A, Sridhar KS, Ardalan B. Phase II trial of weekly bolus PALA and high dose 24 hr 5-fluorouracil (5-FU) infusion in advanced non-small cell lung cancer (NSCLC).


71. Ucar A, Sridhar KS, Chatoor H, Ardalan B. Phase II trial of weekly low dose bolus PALA and high dose 24 hr 5-fluorouracil (5-FU) with high dose leucovorin


81. **Ardalan B**, Deng Z. M 5-Flouro-2'-deoxyuridine induced apoptosis and decreased BCL-2 protein expression in cancer cell lines. AACR 1999

82. **Ardalan B**, L. Sparling, K.S. Sridhar, J. Hurley, L. Feun, S. Richman, K. Hamilton. Phase II Trial of High Dose 24-hour Infusion of Fluorodeoxyuridine (F UdR) in Patients with Metastatic Colorectal Cancer (Previously failed multiple chemotherapeutic modalities.) ASCO 1999


84. **Ardalan B**, I.G. Kaklamanos, A.S. Livingstone, D. Franceschi, O.F. Bathe, T.D. Korensky, L. Sparling, M. J. Boyle - Neoadjuvant and Adjuvant Cisplatin, Paclitaxel (TAXOL), 5-fluoro-deoxyuridine (F UdR) and Leucovorin without


87. Abdulla A, Subbarayan PR & Ardalan B Standardization of a strategy to analyse tandem repeats in the 5'UTR of hTS gene, University of Miami, Department of Biology Undergraduate Research Seminar, Coral Cables, Fl, USA - 2002

88. Elena L.Paley, Subbarayan R.Pochi, **Ardalan B** and Theodore J. Lampidis. - Hypoxia-Inducible Transcriptional factor –1 is associated with mitosis under normoxia and hypoxia. - 2004

89. Subbarayan PR, Sarkar M, Nelson G. Shabashvili D & **Ardalan B**. Akt1/PKB pathway is affected in 5-FU resistant HT-29 cells. American ASCO 95th Annual Meeting, March 27-31, Orlando, FL. - 2004


91. J Parra, M Hickeson, **Ardalan B**, A Ribeiro, A Livingstone, M. Lima and D Franceschi . Positron emission tomography (PET) in locally advanced esophageal cancer (EC) 2004


94. Subbarayan PR, Lee P and **Ardalan B**, Inhibition of RNA synthesis by 5-fluorouridine accounts for its cytotoxicity on colorectal cancer cells in vitro, American Association for Cancer Research 96th Annual Meeting, April 16-20, Annaheim, CA, USA - 2005

95. Subbarayan PR, Wang PG, Lampidis TJ, **Ardalan B** and Braunschweiger P. Increased expression of Glut1 mRNA and protein levels correlates with increased sensitivity to glycol-conjugated nitric oxide donors in different cell types, American Association for Cancer Research 96th Annual Meeting, April 16-20, Annaheim, CA, USA – 2005


97. Neoadjuvant and Adjuvant chemotherapy without radiation for Esophageal cancer- Bach Ardalan, MD, Seth A. Spector, MD, Alan S. Livingstone, MD, Dido
Franceschi, MD, Parviz Ganjei-Azar, MD, Mayra Lima, ARNP, Lynn Sparling, RN, Gail Walker, PhD, Carol P. Bowen-Wells. – ASCO – GI Symposium, San Francisco 2006


101. B. Ardalan, Subbarayan PR, Sarkar M, Nelson G, and Benitez E, Chronic exposure of CRC cell line HT29 to 5-FU or FUR alters multiple independent pathways, American Association for Cancer Research 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA, USA.


103. B.Ardalan, S. Spector, D.Mezentsev, M.Milina, I.Reis, P.Ganjei-Azar, M.Sapp, J.Rios, D.Franceschi, A. Livingstone; Phase II study of neoadjuvant chemotherapy with FUdR (F), Leucovorin (L), Oxaliplatin (O) and Docetaxel (D) (FLOD) in chemo-naive operable esophageal carcinoma, 2007 Gastrointestinal Cancers Symposium, ASCO-GI, Jan.25-27, 2008, Orlando, FL, USA.